Sign In
Buy 1513
HK$31.20
-0.660 (-2.07%)
At Close: Nov 18, 2025
Livzon Pharmaceutical Group Earnings Calls
Sep 30, 2025
HK$0.568 (-13.41%)
| Release date | Oct 23, 2025 |
| EPS estimate | HK$0.656 |
| EPS actual | HK$0.568 |
| EPS Surprise | -13.41% |
| Revenue estimate | 3.085B |
| Revenue actual | 3.109B |
| Revenue Surprise | 0.799% |
Jun 30, 2025
HK$0.786 (25.76%)
| Release date | Aug 20, 2025 |
| EPS estimate | HK$0.625 |
| EPS actual | HK$0.786 |
| EPS Surprise | 25.76% |
| Revenue estimate | 2.742B |
| Revenue actual | 3.382B |
| Revenue Surprise | 23.33% |
Mar 31, 2025
HK$0.755 (1.48%)
| Release date | Apr 21, 2025 |
| EPS estimate | HK$0.744 |
| EPS actual | HK$0.755 |
| EPS Surprise | 1.48% |
| Revenue estimate | 3.135B |
| Revenue actual | 3.394B |
| Revenue Surprise | 8.27% |
Dec 31, 2024
HK$0.461 (7.09%)
| Release date | Mar 26, 2025 |
| EPS estimate | HK$0.430 |
| EPS actual | HK$0.461 |
| EPS Surprise | 7.09% |
| Revenue estimate | 2.774B |
| Revenue actual | 2.905B |
| Revenue Surprise | 4.70% |
Last 4 Quarters for Livzon Pharmaceutical Group
Below you can see how 1513.HK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Dec 31, 2024
Beat
| Release date | Mar 26, 2025 |
| Price on release | HK$26.25 |
| EPS estimate | HK$0.430 |
| EPS actual | HK$0.461 |
| EPS surprise | 7.09% |
| Date | Price |
|---|---|
| Mar 20, 2025 | HK$26.80 |
| Mar 21, 2025 | HK$26.85 |
| Mar 24, 2025 | HK$26.60 |
| Mar 25, 2025 | HK$26.35 |
| Mar 26, 2025 | HK$26.25 |
| Mar 27, 2025 | HK$26.35 |
| Mar 28, 2025 | HK$27.35 |
| Mar 31, 2025 | HK$26.60 |
| Apr 01, 2025 | HK$27.80 |
| 4 days before | -2.05% |
| 4 days after | 5.90% |
| On release day | 0.381% |
| Change in period | 3.73% |
Mar 31, 2025
Beat
| Release date | Apr 21, 2025 |
| Price on release | HK$25.85 |
| EPS estimate | HK$0.744 |
| EPS actual | HK$0.755 |
| EPS surprise | 1.48% |
| Date | Price |
|---|---|
| Apr 14, 2025 | HK$26.20 |
| Apr 15, 2025 | HK$26.10 |
| Apr 16, 2025 | HK$25.70 |
| Apr 17, 2025 | HK$25.85 |
| Apr 18, 2025 | HK$25.85 |
| Apr 22, 2025 | HK$26.60 |
| Apr 23, 2025 | HK$26.80 |
| Apr 24, 2025 | HK$27.00 |
| Apr 25, 2025 | HK$26.70 |
| 4 days before | -1.34% |
| 4 days after | 3.29% |
| On release day | 2.90% |
| Change in period | 1.91% |
Jun 30, 2025
Beat
| Release date | Aug 20, 2025 |
| Price on release | HK$36.64 |
| EPS estimate | HK$0.625 |
| EPS actual | HK$0.786 |
| EPS surprise | 25.76% |
| Date | Price |
|---|---|
| Aug 14, 2025 | HK$35.56 |
| Aug 15, 2025 | HK$36.38 |
| Aug 18, 2025 | HK$36.76 |
| Aug 19, 2025 | HK$37.08 |
| Aug 20, 2025 | HK$36.64 |
| Aug 21, 2025 | HK$38.28 |
| Aug 22, 2025 | HK$37.28 |
| Aug 25, 2025 | HK$37.88 |
| Aug 26, 2025 | HK$38.22 |
| 4 days before | 3.04% |
| 4 days after | 4.31% |
| On release day | 4.48% |
| Change in period | 7.48% |
Sep 30, 2025
Missed
| Release date | Oct 23, 2025 |
| Price on release | HK$31.84 |
| EPS estimate | HK$0.656 |
| EPS actual | HK$0.568 |
| EPS surprise | -13.41% |
| Date | Price |
|---|---|
| Oct 17, 2025 | HK$32.40 |
| Oct 20, 2025 | HK$32.74 |
| Oct 21, 2025 | HK$32.48 |
| Oct 22, 2025 | HK$32.58 |
| Oct 23, 2025 | HK$31.84 |
| Oct 24, 2025 | HK$31.44 |
| Oct 27, 2025 | HK$31.00 |
| Oct 28, 2025 | HK$30.90 |
| Oct 30, 2025 | HK$30.72 |
| 4 days before | -1.73% |
| 4 days after | -3.52% |
| On release day | -1.26% |
| Change in period | -5.19% |
Livzon Pharmaceutical Group Earnings History
Earnings Calendar
FAQ
When is the earnings report for 1513.HK?
Livzon Pharmaceutical Group Inc. (1513.HK) has scheduled its earnings report for Mar 24, 2026 before the markets open.
What is the 1513.HK price-to-earnings (P/E) ratio?
1513.HK P/E ratio as of Nov 18, 2025 (TTM) is 14.90.
What is the 1513.HK EPS forecast?
The forecasted EPS (Earnings Per Share) for Livzon Pharmaceutical Group Inc. (1513.HK) for the first fiscal quarter 2025 is HK$.
What are Livzon Pharmaceutical Group Inc.'s retained earnings?
On its balance sheet, Livzon Pharmaceutical Group Inc. reported retained earnings of HK$3.11 billion for the latest quarter ending Sep 30, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
